Royal Melbourne Hospital set to host preliminary trial for a new stem cell therapy

By Uwear

In an attempt to discover a cure Parkinson’s disease and other brain degeneration diseases, U.S.-based International Stem Cell Corporation (ISCO) will have a world-first trial for an innovative stem cell therapy at Royal Melbourne Hospital.

The trial will be run by ISCO’s Aussie subsidiary, Cyto Therapeutics, and will consist of 12 Parkinson’s patients who will be injected with neural stem cells before being observed for one year. Doctors will monitor the subjects to see if they are able to boost the brain’s capacity to produce and release the chemical messenger dopamine, which is lost in Parkinson’s patients.

RELATED TOPIC: TransMedics creates new Organ Care System being used in Australia

“Dopamine is one of the most critical neurotransmitters or chemical messengers in the brain, and the loss of this neurotransmitter is directly linked to the development of the cardinal features that include stiffness, slowness and shaking,” said Melbourne neurologist Dr. Andrew Evans.

“It’s hoped that through replenishment of the dopamine through these neural stem cells, which show some capacity to differentiate into obviously dopamine producing cells in the annual models, we are hoping to restore some of the functions in patients with Parkinson’s disease.”

RELATED TOPIC: Google Australia supports Aussie children, invests in STEM

Australia was chosen to host the initial phase one of the trial due to its high standard in clinical research as well as its culture of innovation. If the first phase is deemed successful, larger trials in Australia, the U.S. and Europe will commence within the next couple years.

With Japan establishing itself as the global hub of stem cell technology, stem-cell based regenerative medicines can be made available in Japan only if it makes it past phase-two trials. So unlike other countries, this will require a third round of clinical testing.

RELATED TOPIC: Will Australia change cranial reconstruction with new 3D printing technology?

Parkinson’s disease affects nearly 10,000 people across the globe, including 80,000 Australians, with symptoms including movement restrictions, shaking, dementia and other behavioural problems. According to ISCO chief scientific officer Dr. Russell Kern, a single injection of the stem cells could generate a lifetime supply of neurons.

Successful preliminary and subsequent trials would be a revolutionary breakthrough for using stem cells to treat other diseases that cause brain degeneration, including ALS or Lou Gehrig’s disease.

RELATED TOPIC: 4WEB Medical brings 3D printing implants to Australia

Because so many Aussie companies are creating new ways of extracting stem cells from human tissues such as flood and fat, the federal government views stem cell technology as a way to stimulate the nation’s economy.

Let's connect!  

Check out the latest edition of Business Review Australia!




Featured Articles

Top 10 female executives leading Japan's charge for change

As Japan pledges a 30% target for women executives at big firms by 2030, we spotlight 10 female corporate leaders blazing a trail in the country

Top 10 most valuable unicorns in China – phones to drones

Home to the world’s most valuable unicorn, not to mention the fastest growing, China may be trailing the US on numbers, but it is catching up – and fast

Top 10 fastest-growing energy companies in the APAC region

Business Chief takes a look at the top 10 fastest-growing energy companies in the APAC region, according to rankings from S&P Global Commodity Insights

Top 10 Chief Financial Officers in India

Corporate Finance

Top 10 largest companies Malaysia and the CEOs who helm them

Leadership & Strategy

5 high-profile CEO moves across Asia-Pacific this month

Leadership & Strategy